FDA warns of unregistered drugs in market

The Food and Drug Administration (FDA), which regularly inspects drugs in the pharmaceutical market for quality, issued a notification on 26 March to inform the public about the sale of unregistered medicines in the market.
The FDA issued a notification to inform the public about the differences between registered medicines and illegal ones, highlighting the discovery of drugs, including some commonly used ones on the market, that lack quality, effectiveness, or safety guarantees.
When the FDA inspected seven cosmetics that were distributed locally in 2023, they found the products contained prohibited chemicals that can cause skin irritation, swelling, rash, numbness, muscle cramps, fatigue, headaches, dizziness, and depression. Moreover, prolonged exposure can also lead to kidney failure and other chronic diseases. Therefore, the FDA warns the public of these unsafe cosmetics on 26 March.
The warning also informs cosmetic importing companies, distributors, wholesalers, and retailers to practice industrial ethics by refraining from distributing unregistered cosmetics declared unsafe for use. The relevant authorities will take legal action against them under Section 3, Chapter 3 (D) of the Public Health Law for non-compliance. — TWA/TH